Also worth noting the the Lenzi study and current

Also worth noting the the Lenzi study and current trial are laden with exclusion criteria.

And GM-CSF is only elevated in 20-30% of severe patients. Lenzi appears to be useful, but it's not in the same ballpark as Leronlimab.